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ABSTRACT 
 
 
Shaklawoon, Noura. M.S. Microbiology and Immunology Graduate Program,  
Wright State University, 2013. Establishment of a quiescence HSV-1 infection in L929 
fibroblasts and Neuro-2A cells by a nucleoside analogue acyclovir. 
 
Herpes simplex type 1 (HSV-1) quiescent infection was established in L929 cells, 
murine fibroblasts, and in Neuro-2A (N2A) cells, mouse neuroblastoma, by treating them 
with the nucleoside analogue acyclovir (ACV) 24 hours before infection. Subsequent 
release of virus from the non-productive state was accomplished by treating the cells with 
the histone deacetylase inhibitor trichostatin A (TSA). Treatment of both L929 and N2A 
cell lines with ACV 24 hours before infection induced protection from HSV-1 cytopathic 
effect. A quiescent state was confirmed by absence of virus plaques when supernatant 
fluids from ACV-treated HSV-1 infected cultures were titered on Vero cell monolayers. 
Acyclovir was maintained in the cell culture medium for one day before infection and 
two days post infection. Removal of ACV from the culture medium did not permit 
reactivation of virus as determined by virus plaque assays. Virus reactivation was 
confirmed in ACV- treated HSV-1 quiescent cells by examining cell lysates for virus 
plaque forming units. Four days post infection of ACV-treated cells, culture medium was 
removed and replaced with medium containing TSA. Supernatant fluids from cultures 
treated with TSA showed virus production in plaque forming assays on Vero cells. Media 
from both lytically infected cultures and TSA reactivated cultures contained productive 
virus; however, media from latently infected cultures did not show the presence of 
infectious virus. Treatment of L929 cells with ACV 2 hours after infection with HSV-1 
induced a quiescent effect better than treatment of the cells with AVC 24 hours before 
iv 
infection, because higher cell densities survived. As expected quantitative real-time 
polymerase chain reaction (qPCR) analysis of HSV-1 transcripts showed about one fold 
increase in Latency Associated Transcript (LAT) and a decrease in the lytic cycle infected 
cell protein (ICP0) in ACV-treated HSV-1 infected L929 cells at 16 hours post infection 
as compared with the untreated HSV-1 infected L929 cells. At the same time, lytic cycle 
infected cell protein (ICP27) showed a one and half fold increase in ACV-treated HSV-1 
infected L929 cells compared with the untreated HSV-1 infected L929 cells. At 48 hours 
post infection, both infected cell proteins (ICP27 and ICP0) and LAT were observed at 
low levels in ACV-treated HSV-1 infected L929 cells compared with the lytically infected 
control cells. In N2A cells, LAT was noted at low level in ACV-treated HSV-1 infected 
N2A cells as compared with the untreated HSV-1 infected N2A cells at 16 hours post 
infection. At the same time, ICP0 decreased and ICP27 showed approximately one fold 
increase in ACV-treated HSV-1 infected N2A cells as compared with the untreated HSV-1 
infected N2A cells. At 48 hours post infection, both lytic cycle transcripts (ICP27 and 
ICP0) and LAT were observed at low levels in ACV-treated HSV-1 infected N2A cells as 
compared with untreated HSV-1 infected control N2A cells. LAT was present but not 
significantly increased in both cell lines although they were latently infected and 
maintained with the ACV treatment. 
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INTRODUCTION 
 
Herpes simplex virus (HSV) is a member of Herpesviridae family of large double 
stranded DNA viruses. Herpes simplex virus type 1 (HSV-1) and herpes simplex type 2 
(HSV-2) are able to establish both lytic and latent infections. HSV is a neurotropic virus 
which can establish a latent infection within the sensory neurons in trigeminal ganglia 
(Nicoll et al., 2012). The mechanism by which HSV enters latent infection remains poor-
ly understood. HSV-1 is usually associated with oral mucosa infections and encephalitis.  
HSV-2 usually causes genital infections and can be transmitted from infected mothers to 
neonates (Whitley and Roizman, 2001). About 90% of the population worldwide is in-
fected with HSV-1 (Nicoll et al., 2012). The infection ranges from mild symptoms to 
death. Following primary HSV-1 replication at the oral mucosa, the virus infects the pri-
mary efferent of sensory neurons that innervate these tissues and reaches the nerve cell 
body located in sensory ganglia by retrograde microtubule-associated transport (Nicoll et 
al., 2012). Inside the cell body of sensory neurons, the virus causes either a lytic replica-
tion cycle or a latent infection. Most of the neurons will survive the infection and the vi-
rus will enter a latent cycle. However, some neurons will be destroyed because of the 
productive infection (Miller et al., 1998; Danaher et al., 1999b). During latency, the virus 
genome assumes a linear pattern which is transcriptionally repressed except for the region 
that encodes the latency-associated transcript (LAT) (Coleman et al., 2008). Exposure to 
heat, stress, ultraviolet light, or trauma, can cause spontaneous occasional reactivation of 
HSV-1 (Kuhn et al., 2012).  The reactivated virus reenters the replication cycle forming 
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an infectious virus, which is transported anterograde back to the epithelial cells and be-
gins re-infection and subsequent transmission (Danaher et al., 1999b). 
Many stimuli have been shown to induce HSV-1 reactivation in vivo and in vitro. 
However, the molecular events of virus reactivation are not well known because of the 
absence of an effective murine model for in vivo and in vitro HSV-1 latency establish-
ment and reactivation.  Acyclovir (ACV), a nucleoside analogue, has been used to induce 
HSV-1 latency in vitro. A combination treatment of the human fetus lung fibroblasts 
(HFL-F) with ACV and interferon- α (INF-α) resulted in HSV-1 latency that continued 
after the removal of the drug (Scheck et al., 1986). However, Rong et al., 1988 showed 
that ACV induced HSV-1 latency in rabbit corneal cells (SIRC) and removal of the ACV 
led to reactivation of the virus. Interferon- γ (IFN-γ) plays a role in the cellular response 
to HSV-1. Frey et al., 2009 showed that IFN-γ can inhibit HSV-1 replication in L929 fi-
broblasts, but not in HEL-30 keratinocytes. The HEL-30 cells were resistant to IFN-γ 
suppression because of up regulation of the protein suppressor of cytokine signalling-1 
(SOCS-1) in these cells. Histone modification is involved in viral gene expression during 
lytic and latent infection. Quiescently HSV-1 infected human fetal lung fibroblasts 
(MRC-5) showed deacetylated histones in their repressed genome structure. Genome de-
repression by HSV-1 superinfection or ICP0 delivery by recombinant adenovirus resulted 
in re-enrichment of the viral DNA with acetylated histone (Coleman et al., 2008). In ad-
dition, histone deacetylase inhibitor, trichostatin A (TSA), induced HSV-1 production 
from quiescently infected neuronally differentiated pheochromocytoma (PC12) cells. 
Furthermore, the LAT gene was the only viral gene that accumulated in response to inhi-
bition of deacetylation by using TSA. These observations indicate that LAT promoter is 
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transcriptionally active. LAT was not required for the reactivation process because LAT-
deleted virus reactivated similarly to the wild type virus after TSA and heat stress appli-
cation (Danaher et al., 2005).  
Hypothesis: 
Since acyclovir (ACV) interferes with HSV-1 replication by binding viral thymidine 
kinase and blocking viral DNA synthesis, ACV may render murine L929 fibroblasts 
and neuro-2A cells susceptible to HSV-1 induced latency. If latency can be estab-
lished, HSV-1 will be reactivated following treatment with trichostatin A (TSA), a 
histone deacetylase inhibitor, which increases acetylation and relaxation of chroma-
tin, permitting virus replication. 
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LITERATURE REVIEW 
 
HSV-1 LYTIC INFECTION 
Lytic HSV-1infection occurs in epithelial cells. The virus attaches to heparan 
sulfate, cell surface membrane receptor, (Wudunn and Spear, 1989). Attachment of the 
virus to the host cell is facilitated by viral glycoproteins B and C (Rajcani and 
Durmanova, 2000). Glycoprotein D facilitates virus adsorption to the host cell and 
glycoproteins H and L are responsible for membrane penetration of the virus into the host 
cell (reviewed in Rajcani and Durmanova, 2000). Furthermore, Dingwell et al., 1995, 
demonstrated that glycoprotein E and I are responsible for HSV-1 spreading from one 
neuron to another neuron. 
HSV-1 lytic infection involves ordered expression of several classes of viral genes 
that consist of structural and nonstructural components (Honess and Roizman, 1974). The 
cascade starts with expressing immediate early (IE) genes (α genes), followed by that of 
early (E) genes (β genes), DNA replication and late (L) genes (γ genes).The maximum 
rate of synthesis by the α genes occurs 3 to 4 hours post infection. The β genes are 
responsible for the highest rate of directing protein synthesis 5 to 7 hours post infection. 
The γ genes directing protein expression increases until 12 hours post infection. Use of 
the protein synthesis inhibitor cycloheximide confirmed that IE polypeptides expression 
occurs without prior viral protein synthesis, but E and L polypeptides expression needs 
preceding IE protein synthesis (Honess and Roizman, 1974).  
The IE genes consist of infected cell proteins (ICP0, ICP4, ICP22, ICP27, and 
ICP47) and Us1.5, N-terminally truncated form of ICP22 (reviewed in Nicoll et al., 2012). 
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Wysocka and Herr, 2003 revealed that IE genes have VP16-response elements (VRE) 
within their promoters. The virion protein (VP16) is the main factor that activates 
transcription of these genes (Figure 1). 
  Following the entry of the virus to the cell, the viral capsid facilitates the release 
of viral DNA into the nucleus (Nicoll et al., 2012). In the cytoplasm, VP 16 binds host 
cell factor-1 (HCF-1) protein, which has a nuclear localization sequence, leading to the 
entry of VP 16 into the nucleus (Boissiere et al., 1999). Once in the nucleus, both VP 16 
and HCF-1 proteins form a trimeric complex with another protein, Octamer binding 
protein- 1 (Oct-1) on the IE promoter and start IE gene transcription (Wysocka and Herr, 
2003). 
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Figure 1: HSV-1 lytic infection and gene expression (Adapted from Wysocka and 
Herr, 2003). 
 
 
HSV-1 LATENT INFECTION 
Lack of in vitro cell line model has limited our understanding to HSV latency and 
reactivation. A cell culture model would permit inspection of the events leading to latency 
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to a single cell line without the effect of immune response that would alter virus behavior 
in the cell (Danaher et al., 1999a). Latent infection is characterized by presence of non-
replicating viral genome in the infected neuron from which the virus can be reactivated 
intermittently. The lytic infection genes are not expressed and the host cell survives the 
infection. The immune system cannot identify latently infected neurons. Latent herpes 
virus infection can be divided into three phases: establishment of latency, maintenance of 
latency, and reactivation from latency (Figure 2). 
 
Establishment of latency 
In the establishment phase, the virus enters the neuronal cell in which the viral 
genome remains transcriptionally quiescent. Thus, the integrity of the neuron is not 
compromised, as the cytopathic effect of the productive infection does not occur (Wagner 
and Bloom, 1997). During the establishment of latent infection, gene expression is 
limited to a gene located within the long repeat elements of the viral genome. 
Transcription of this gene results in generation of the latency-associated transcripts (LATs) 
(Zabolotny et al., 1997). Establishment of latency may result from the inability of IE 
genes to induce lytic infection. Marshall et al., 2000 showed that HSV-1 established 
latency in mice in the presence of impaired IE gene expression and that latency was not 
affected by restoration of VP16, ICP0, or ICP4 coding sequences. These observations 
suggest that the latency is increased when IE gene expression is inadequate to initiate the 
lytic infection. Latent HSV-1 presents in the nucleus of infected neurons (Nicoll et al., 
2012). 
During latency, the ability of VP 16 to initiate lytic gene expression may be 
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inhibited by a defect in VP 16 transport from nerve endings to the neuronal cell body, or 
due to the presence of this protein in reduced amounts in the neurons (reviewed in Miller 
et al., 1998).  
In addition, two competitive inhibitors (transcription factors) for VP 16 were 
demonstrated: the octamer-binding protein (Oct-2) (Lillycrop et al., 1991) and N-Oct3 
(Hagmann et al., 1995). These two factors are present in the sensory neurons and they 
compete with VP 16 for the binding of α gene promoter. Another factor for the establish-
ment of latency in sensory neurons is failure of VP 16 to form a complex with HCF-1. In 
sensory neurons, HCF-1 protein is present in the Golgi apparatus in the cytoplasm instead 
of the nucleus.  Upon reactivation of HSV-1, the HCF-1 protein moves to the nucleus 
(Kolb and Kristie, 2008). 
Octamer binding protein- 1 (Oct-1) is present in almost all cell types including 
proliferating cells of neuronal origin, but it is down regulated in mature non-dividing neu-
rons (Lakin et al., 1995), contributing to the failure of VP 16 to form a complex which is 
important for IE gene transcription during lytic cycle. 
 
Maintenance of latency 
During the maintenance phase of latency, a reservoir of the viral genomes should 
be increased on reactivation. To date, no viral gene expression appears to be needed for 
latency maintenance in sensory ganglion (Wagner and Bloom, 1997; Miller et al., 1998). 
Wilcox and Johnson, 1988 revealed that nerve growth factor (NGF) is essential 
for HSV-1 latency maintenance in sympathetic ganglion neurons treated with acyclovir 
(ACV) in vitro. They showed that NGF withdrawal caused reactivation of these neurons. 
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HSV-1 latency was induced by the using of ACV in these cells, although the role of NGF 
in latency maintenance is controversial. 
Reactivation from latency 
Reactivation of HSV-1 from latency includes a shift from quiescence to virus rep-
lication state within neurons of sensory ganglion. In humans, HSV-1 reactivation can be 
spontaneous or as a result of exposure to UV irradiation, emotional stress, fever, or im-
mune suppression. Reactivation causes shedding of the virus transported through neu-
ronal axons to the epithelial cells where the virus can replicate and start a lytic cycle. 
In culture, researchers have found different stimuli that can reactivate HSV-1 from 
latency. Nerve growth factor deprivation from neurons resulted in HSV-1 reactivation 
from latency (Wilcox and Johnson, 1988). Heat stress can reactivate HSV-1 from latency 
in PC12 cells (Danaher et al., 1999b; Miller et al., 2003; Danaher et al., 2005). Histone 
deacetylase inhibitors Trichostatin A (TSA) (Danaher et al., 2005; Roehm et al., 2011; 
Kuhn et al., 2012) or sodium butyrate (Danaher et al., 2005) can induce HSV-1 produc-
tion from a quiescence state in neuronal cells by acceleration of HSV-1 genome hyper 
acetylation and relaxation. Danaher et al., 2005 examined the viral gene response to TSA 
and found only LAT accumulated in response to TSA reactivation. However, they showed 
that LAT is not necessary for this reactivation because the LAT mutant HSV-1 reactivated 
as the wild type virus in the neuronal cells. Forskolin, which increases the cyclic adeno-
sine monophosphate (cAMP) signaling, can induce HSV-1 reactivation in neuronal cell 
line (Danaher et al., 1999a; Miller et al., 2003; Danaher et al., 2005). Activation of ade-
nylate cyclase causes elevation of cAMP in the cells.  Then cAMP binds protein kinase A 
(PKA) that can release catalytic subunits leading to phosphorylation of specific transcrip-
10 
tion factors. Increased levels of cAMP may contribute to HSV-1 reactivation because 
LAT promoter is cAMP responsive. Phosphorylation may also include transcription fac-
tors needed for ICP0 and ICP4 expression (reviewed in Miller et al., 1998). HSV-1 can be 
reactivated by superinfection with cytomegalovirus (CMV) (Scheck et al., 1986) or ade-
novirus vector encoding exogenous HSV-1 ICP0 which de-presses the quiescent viral ge-
nome (McMahon and Walsh, 2008; Coleman et al., 2008).  
In experimental animals, hyperthermia was efficiently induced HSV-1 reactivation 
from latently infected mice (Sawtell and Thompson, 1992). HSV-1 reactivation was lim-
ited to few neurons following stimulation of the whole ganglion. 
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Figure 2:  HSV-1 lytic and latent infection (adapted from Miller et al., 1998). 
 
FUNCTION OF LAT 
Transcription of LAT results in production of an 8.3 kb ‘minor LAT’ primary 
transcript, which is then spliced to produce a stable 2.0 kb intronic and  an unstable 6.3 
kb exonic RNA (Figure 3). The 2.0 kb intron is furthermore spliced to produce an addi-
tional stable 1.5 kb intron. The last two RNA species are named as the “major LATs”. 
The minor and major reflect the abundance of these transcripts in the experimental sys-
tems (Zabolotny et al., 1997). A protein encoded by the LAT has not been detected 
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(Doerig et al., 1991; Umbach et al., 2008). However, Doerig et al., 1991 showed that 
LAA, latency-associated antigen, was present in primary neurons latently infected in 
vitro.  This antigen was not present in neurons with mock infection, in Vero cells with 
lytic infection, or in neurons with latent infection by a mutant virus carrying a deletion in 
the LAT gene. The function of this protein was not clear. They found that LAT mutant 
virus established a latent infection and reactivated from explanted trigeminal ganglia of 
mice as the wild type virus. These observations suggest that LAA may stay inactive dur-
ing the latent infection and be activated by extracellular stimuli that trigger virus reactiva-
tion (Doerig et al., 1991).  
To date, the function of LAT is still not well understood. It is surprising that LAT 
expression is not an absolute indication for latency establishment (Javier et al., 1988), as 
LAT defective HSV-1 can establish latent infection in mice (Block et al., 1990). In con-
trast, Thompson and Sawtell in 1997 revealed that the LAT gene has a role in establish-
ment of latency, but LAT has no direct role in the HSV-1 reactivation. They found that 
about 30% of the TG neurons in mice infected with LAT
+
 HSV-1 harbored latent virus. 
However, 10% of the neurons in mice infected with LAT-null viruses were positive for 
HSV-1 DNA. To confirm the role of LAT deletion in the decreased frequency of latency 
establishment, they rescued the LAT gene by repair of the LAT genome and by expres-
sion of the 2.3-kb ApaI fragment that contains the major LAT sequences. The rescued 
LAT gene showed wild-type establishment and reactivation. HSV-1 with mutated IE gene 
can establish latency (Marshall et al., 2000).  
 The LAT exonic region functions as a primary microRNA (miRNA) precursor 
that encodes four different miRNAs in HSV-1 infected cells (Umbach et al., 2008). The 
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miR-H2-3p is transcribed as antisense to ICP0. The miR-H2-3p is able to reduce ICP0 
protein expression, but does not significantly affect ICP0 mRNA levels. The miR-H6 in-
hibits expression of ICP4. These results may explain the ability of LAT to induce latency 
(Umbach et al., 2008; Umbach et al., 2009). These miRNA precursors act as post-
transcriptional regulators of viral gene expression to help in induction and maintenance of 
HSV-1 latency in the host cell. 
 
 
 
Figure 3: The LAT region of HSV-1 genome (Adapted from Nicoll et al., 2012). 
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IMMUNE RESPONSE TO HSV-1 
It is important to understand the mechanisms that control the latency of HSV-1 
because its reactivation from latency is associated with pathological disease due to 
shedding of the reactivated virus from the sensory ganglia (Knickelbein et al., 2008). 
Knickelbein et al., 2008 found that CD8
+
 T cells can inactivate HSV-1 without inducing 
neuronal apoptosis. They showed that CD8
+
 T cell lytic granules, containing granzyme B, 
can destroy the HSV-1 immediate early protein, ICP4, which acts as transactivator of β 
genes required for viral DNA replication.  
Theil et al., 2003 have shown that HSV-1 latency is accompanied by chronic 
inflammatory response without neuronal damage. Latently HSV-1 infected trigeminal 
ganglia (TG) showed infiltration with CD3
+ 
and CD8
+
 T cells, CD68-positive 
macrophages, interferon-γ, tumor necrosis factor-α, IP-10, and RANTES. Researchers 
suggested that the presence of the immune cells and elevated levels of cytokines inside 
the neurons of latently infected trigeminal ganglia may explain why immunosuppressive 
drugs cause viral reactivation.  
CD8
+
 T cells and macrophages and their cytokine, tumor necrosis factor, have a 
role in maintaining HSV-1 latent in the trigeminal ganglia. However, natural killer cells 
and γδ T cells and their cytokine gamma interferon play a role in preventing viral 
replication during the lytic infection (Liu et al., 1996).  
Feldman et al., 2002 explained the immune cells infiltration in latently infected 
trigeminal ganglia by spontaneous reactivation of some neurons leading to expression of 
HSV-1 lytic cycle transcripts. Because of absence of detectable virus in latently infected 
trigeminal ganglia, they called this situation a spontaneous molecular reactivation. 
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T lymphocytes, CD8
+
 T cells, have an immunological role against viral infection. 
CD8
+
 T cells can recognize viral antigens produced by viral infected cells and attack 
these cells. HSV-1 has developed different ways to avoid the immune response. HSV-1 is 
able to escape the immune response of the CD8
+
 T cells in the neuronal tissue by 
expression of ICP 47 protein, an HSV-1 immediate protein (Goldsmith et al., 1998). The 
ICP47 inhibits HSV-1 infected cell recognition by CD8
+
 T by inhibiting the transporter 
associated with antigen presentation (TAP). The ICP 47 blocks the expression of HSV-1 
antigens on the MHC I on the surface of viral infected cells. HSV-1 with ICP47 mutation 
is less neurovirulent than wild-type HSV-1 in mice, but both of them are able to replicate 
normally in epithelial tissues. The ICP47 mutant HSV-1 showed reduced neurovirulence 
in immunologically normal mice and T cell–deficient mice after reconstitution with CD8
+
 
T cells. 
Researchers have shown another way by which HSV-1 can evade the immune 
response by SOCS-1 expression, a suppressor of cytokine signaling-1(Frey et al., 2009). 
They found that HSV-1 was resistant to antiviral effect of IFN-γ in keratinocytes. HSV-1 
infected keratinocytes exhibited high levels of SOCS-1 mRNA and protein. HSV-1 
prevented IFN-γ signaling by inhibition of STAT1α activation. ICP0 has a role in the 
activation of the host gene SOCS-1 (reviewed in Frey et al., 2009). 
 
MODELS FOR STUDYING HSV-1 LATENCY 
Animal models rabbits, guinea pigs, and mice have been used to study HSV 
latency and reactivation. These animal models gave us the vast majority of our 
understanding of HSV latency and reactivation. However, the use of these models is 
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limited because the pattern of infection is strain specific, the neurovirulence of HSV in 
these animals can be altered by gene manipulation to understand viral gene relationship 
and the inadequate number of neurons latently infected with the virus (Wagnar and 
Bloom, 1997).  
The mouse model is most commonly used to study HSV-1 latency. After 
peripheral inoculation of the virus into the cornea or footpad of the mouse, the virus 
replicated in the epithelial cells then transported by axons to the regional sensory 
ganglion. Three to ten days post infection the virus can be discovered in sensory ganglion. 
The immune system then clears the lytic infection and latent infection is established 
(Nicoll et al., 2012). Reactivation usually does not occur spontaneously, and it can be 
carried out by in vivo induction of reactivation by hyperthermia (Sawtell and Thompson, 
1992) or by sensory ganglion explantation into cell culture (Kuhn et al., 2012; Devi-Rao 
et al., 1994; Camarena et al., 2010).  
Rabbit corneal inoculation has also been used as an animal model. The virus 
reactivation can be spontaneous or can be induced. In vivo induction of reactivation can 
be conducted by application of transcorneal iontophoresis of epinephrine (Danaher et al., 
2005) or intravenous injection of cyclophosphamide followed with intravenous injection 
of dexamethasone (Miller et al., 2003).  
In vitro, cell culture models are superior to the animal models because they allow 
observing the virus at the cellular level without the effect of immune response and it is 
easier to deal with cells than with whole animals. Rat pheochromocytoma (PC12) 
neuronally differentiated cells have been used as a model for HSV-1 latency 
establishment with ACV (Danaher et al., 1999a; Miller et al., 2003; Danaher et al., 2005; 
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Danaher et al., 1999b). Kuhn et al., 2012 used geniculate ganglion neurons as a model for 
latency induction with ACV, and they used HSV-1 GFP-tagged DNA where GFP-positive 
cells detected by fluorescent microscopy. In cell culture models, latent virus can be 
confirmed by absence of productive virus from plaque assays of culture media on Vero 
cells. However, lytically infected or reactivated cultures show infectious virus and plaque 
formation. Coleman et al., 2008 used Human Fetal Lung Fibroblast Cells (MRC-5 Line) 
as latency model. Latency was established by infecting the cells with replication 
defective HSV-1 containing IE gene mutation. Reactivation was induced by 
superinfection with HSV-2 or ICP0 delivery by recombinant adenovirus vector. In culture 
models in vitro, the viral genome was found depressed and circular during latency as is 
found in vivo. However, LAT expression and reactivation have been seen only in 
neuronal cells. On the other hand, Scheck et al., 1986 have shown that in vitro HSV-1 
latency can be established in human fetus lung fibroblast (HFL-F) cell line by using ACV 
and human leukocyte interferon (IFN-α). Virus reactivation was achieved by human 
cytomegalovirus superinfection or by reducing the incubation temperature from 40.5°C to 
37°C 
 
ACV BIOCHEMISTRY AND MECHANISM OF ACTION 
Acyclovir, 9-(2-hydroxyethoxymethyl) guanine, is acyclic purine nucleoside 
analogue (Figure 4) (Elion, 1982).  
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Figure 4: Comparison between structure of guanosine and acyclovir (Adapted from 
http://en.wikipedia.org/wiki/Aciclovir). 
 
 
Acyclovir has potent inhibitory and selectivity for herpes viruses, especially 
herpes simplex viruses types 1 and 2 and varicella zoster virus (Elion, 1982). The 
selectivity of this drug to herpes viruses is due to the ability of these viruses to activate 
the drug by viral thymidine kinase (TK) to acyclovir mono phosphate. Acyclovir 
monophosphate is then converted to a triphosphate by cellular enzymes. Acyclo-GTP 
binds strongly to herpes virus DNA polymerases than to the cellular DNA polymerases 
and terminates DNA synthesis (Figure 5). Acyclo-GTP persisted in HSV-infected cells for 
many hours after acyclovir removal from the medium (Elion, 1982; Furman et al., 1981). 
In addition, (Furman et al., 1981) showed that Acyclo-GTP formation occurs even in the 
uninfected cells, but the enzymes responsible for first ACV phosphorylation are unknown. 
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Figure 5: Acycovir mechanism of action (Adapted from 
http://depts.washington.edu/hivaids/derm/case2/discussion.html). 
 
 
 
TSA MODE OF ACTION 
Trichostatin A (7-[4-(dimethylamino) phenyl]-N-hydroxy-4, 6-dimethyl-7-
oxohepta-2, 4-dienamide) (TSA) is an antifungal antibiotic. Yoshida et al., 1990 showed 
that TSA can reversibly suppress cell cycle at G1 and G2 phases of the normal mouse 
diploid fibroblasts. It causes hyper acetylation of histones by inhibition of histone 
deacetylases. They found that TSA did not interfere with activity of other enzymes such 
as protein kinase, protein phosphatase, DNA topoisomerase, and calmodulin in vitro. 
Thus it can be used for biological analysis without side effects. 
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Trichostatin A has selectivity to inhibit class I and II HDACs (Dokmanovic et al., 
2007). Both class I and class II deacetylases have zinc in their catalytic sites to which the 
TSA can bind and inhibit these enzymes. However, class III HDACs have sirtuin proteins 
in the catalytic site and are not inhibited by TSA. Histone deacetylase inhibitors cause   
hyperacetylation of histones, leading to alteration of gene expression. TSA interferes with 
the removal of acetyl group from histones leading to changing the ability of DNA 
transcription factors to access DNA in the chromatin structure. 
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MATERIALS AND METHODS 
Cell culture 
Cell lines used in this study were: L929 fibroblasts (CCL-1, ATCC) derived from C3H 
mouse connective tissue, N2A cells (CCL-131, ATCC) derived from mouse 
neuroblastoma cells, and Vero cells (CCL-81, ATCC) derived from the kidneys of African 
Green Monkeys. The cells were cultured in Dulbecco's Modified Eagles Medium 
(DMEM), supplemented with 10% heat inactivated fetal calf serum (FCS) and 
gentamicin solution 50 µg /ml of the medium. Cells were grown on 100 mm² (L929 and 
Vero cells) and 60 mm² (N2A cells) tissue culture dishes and incubated in a humidified 
incubator at 37°C and 5% CO2. The N2A cells were not differentiated. Cell culture 
dishes and the culture medium were purchased from Fischer Scientific, Pittsburgh, PA. 
 
Virus 
Herpes simplex virus-1 (Syn 17+ strain) (obtained initially from Dr. Nancy Sawtell, 
Children's Hospital Medical Center, Cincinnati, OH) was propagated in Vero cells. The 
Vero cells were grown in 100 mm² culture dishes as a monolayer and, at 90-100% 
confluency, cells were infected with HSV-1 at 0.1 MOI. Cytopathic effect (cells rounding 
and detaching from the bottom of the dish) appeared by microscopic examination 3-5 
days post-infection. Then, the cells were harvested and the medium was stored as virus 
stock in 200 µl aliquots at 80°C. Plaque assay was performed using Vero cells to 
determine the virus plaque forming unit per milliliter (PFU). 
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Nucleoside analogue agent 
Acyclovir (Sigma; St. Louis, MO) was purchased as a powder. A stock solution of 400 µg 
/ml was prepared in DMEM medium, supplemented with 2% FCS and maintained at 2-
8°C for 2 weeks. Additional dilutions were made prior to use.   
 
Histone deacetylase inhibitor 
Trichostatin A (Sigma; St. Louis, MO) was purchased as a solution in DMSO and stored 
at -20°C. Dilutions were freshly made in the culture medium prior to use. 
 
HSV-1 replication suppression  
L929 cells  
ACV treatment before infection (protocol 1) 
L929 cells were cultured in 24 well plates at a seeding density of 2.5x10
4
 to 3x10
4
 in each 
well and incubated overnight. The next day, at 70-80% confluency, cells were treated 
with ACV at different doses (40, 20, and 10 µg /ml of medium) 24 hours before infection 
(Danaher et al., 2005).  At 100% confluency, HSV-1 at 0.1 MOI was added onto L929 
cell monolayer and incubated for 2 hours at 37°C. Then, the virus inoculum was aspirated 
and the medium containing ACV was added to the plates. The plates were incubated at 
37°C in 5% CO2 for 48 hours (Frey et al., 2009). Untreated L929 cells (control cells), 
HSV-1 infected non ACV suppressed cultures (positive infection control), and ACV 
suppressed non-infected cultures (toxicity control) were maintained for each experiment 
(Rong et al., 1988).   At 48 hours post infection, the cytopathic effect of HSV-1 was 
determined: cells were rinsed with PBS and fixed with 4% formaldehyde for 10 minutes, 
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then stained with 0.5% crystal violet for 5-7 minutes. The cells were then rinsed with 
water and allowed to dry at room temperature overnight. Plates were scanned on an HP 
Scan Jet 5300C. Pixel densities of the scanned plates were determined by using the NIH 
Image J program (Frey et al., 2009).  
 
ACV treatment after infection (protocol 2) 
The L929 cells were plated in 24 well plates in 10% DMEM and cultured overnight.  The 
following day, cells were infected with HSV-1 at 0.1 MOI. After 2hours, the residual 
virus was removed and the cells were incubated in culture medium containing ACV for 
48 hours (Rong et al., 1988). The cytopathic effect was analyzed as discussed in protocol 
1. 
 
N2A cells 
N2A cells were plated in 24 well plates at a seeding density of 2x10
4
 to 2.5x10
4 
to each 
well. At 40-50% confluency, cells were treated with ACV at different doses (20, 10, and 5 
µg/ml of medium) 24 hours before infection.  After 24 hours, cells were infected with the 
virus for 2 hours at an MOI of 0.1 at 37°C. Then, the virus was removed and replaced 
with culture medium containing ACV for 48 hours. After 48 hours, the cytopathic effect 
was examined as in the L929 cells.  
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Detection of Latency 
Latent infection (lack of infectious virus in culture medium) of ACV-treated HSV-1 
infected L929 and N2A cells at 48 hours post infection was confirmed by using 
supernatant fluids from ACV-treated HSV-1 infected cultures and titered on Vero cell 
monolayers (Kuhn et al., 2012).  
I. Vero cells were grown in 24 well plates. At 90-100% confluency, the culture 
medium was removed and replaced with 250 µl of supernatant fluids from ACV-
treated HSV-1 infected L929 cultures in each well and incubated for 1 hour for 
adsorption. After 1 hour, the supernatant was replaced with culture medium 
containing methylcellulose and incubated at 37°C in a 5% CO2 for 48 hours when 
they were checked for plaque formation (Shao-Chung et al., 2010). 
II. For confirmation of the maintenance of latency, ACV was removed from the 
ACV-treated HSV- infected L929 and N2A cultures at 48 hours post-infection. 
Then, the cells were incubated in DMEM medium with 10% FCS for an addition-
al 48 hours. At 48 hours, cultures were examined for the presence of productive 
virus using culture supernatant fluids in plaque forming assays on Vero cells. 
 
HSV-1 reactivation 
L929 and N2A cell lysates 
Cells were protected from the cytopathic effect of HSV-1 by ACV treatment. To examine 
if the virus was silenced, cell lysates from the ACV-treated HSV-1 infected cultures were 
examined for PFUs. Cells were grown, treated, and infected as per HSV-1 suppression 
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experiment. At 48 hours post infection, ACV-treated HSV-1 infected cells were collected 
and stored at - 80°C. Virus was released from ACV-treated HSV-1 infected cells by 
formation of lysates collected after two freeze-thaw cycles (Devi-Rao et al., 1994). Vero 
cells were plated in 24 well plates. At 90-100% confluency of the Vero cells, the lysate 
was added on the Vero cell monolayer for adsorption for 2 hours at 37°C. The lysate was 
then aspirated and replaced with culture medium containing methyl cellulose. Plates were 
incubated at 37°C in a 5% CO2 for 2-3 days and checked daily for the HSV-1 cytopathic 
effect (plaque formation). 
 
 Trichostatin A  
L929 cells and N2A cells were grown in 24 well plates overnight.  The following day, the 
cells were treated with ACV for 24 hours before infection. HSV-1 at 0.1 MOI was 
inoculated onto confluent cells and adsorped for 2 hours at 37°C. The virus inoculum was 
then aspirated and replaced with DMEM containing ACV for 48 hours. At 48 hours post 
infection, the ACV containing culture medium was removed and the cells were incubated 
in DMED with 10% FCS for an additional 48 hours. Quiescent cultures (free of 
detectable infectious virus in culture supernatant fluids) were induced by TSA treatment 
using different doses (25 and 50 ng /ml of medium) to activate the virus. At 4 days post 
infection, cultures were induced by incubation in DMED with 10% FCS containing TSA 
and kept at 37°C in a 5% CO2 for 48 hours. After 48 hours, virus release from TSA 
treated cells was examined by titering culture medium on Vero cells (Danaher et al., 2005; 
Kuhn et al., 2012).  
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Quantitative real time PCR for viral gene transcripts 
L929 cells and N2A cells were plated in 60 mm Petri dishes at seeding density of 1-
1.5x10
5
. Cells were maintained in DMEM supplemented with 10% FCS. Cells were 
treated with ACV 24 hours before infection. Cells were infected with HSV-1 at an MOI 
of 1 and maintained in DMEM with 2% FCS containing ACV. Cultures were maintained 
in ACV 1 day before infection and 48 hours post infection.  
 
RNA extraction  
RNA was extracted at different time periods using RNeasy Mini Kit (Qiagen) as per 
manufacturer’s instructions. RNA was extracted 16 hours post infection and at 48 hours 
post infection in presence of ACV. Positive virus control (lytic infection) was run at both 
time periods of RNA extractions. 50 µl of RNA was eluted. The concentration of RNA 
was determined using nanodrop. A total of 10 µg of the eluted RNA was treated with 
DNase I to eliminate DNA contamination using DNase I Amplification Grade (Invitrogen) 
per manufacturer’s instructions. Then, 1 µg of the DNase I treated RNA was reverse 
transcribed to cDNA using Qscript cDNA Synthesis Kit (Quanta) as recommended. 
 
Quantitative real-time PCR (qPCR) 
The relative quantity of cDNA synthesized for HSV-1 transcripts was determined using 
qPCR. The control gene was GAPDH (housekeeping gene), and viral genes were ICP27, 
ICP0, and major LAT. Primers and probes were used as discussed by Danaher et al., 
2005 (Table 1). Primers and probes were purchased from Integrated DNA Technology 
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(IDT) as Prime Time Std qPCR Assay (mixed primers and probes). Probes were labeled 
at the 5’ with the reporter fluorochrome, 6-carboxy-fluorescein (6-FAM), and at the 3’ 
end with lowa Black FQ. Each sample was used in triplicate. Real-time PCR was per-
formed on Applied Biosystems 7900 HT. 20 µl reaction volume was used.  The final 
concentration of 10X Assay was 2 µl of 10X Prime Time Assay, 10 µl of 2X Master Mix 
(Thermo Scientific Maxima Probe/ROX qPCR Master Mix 2X), and 8 µl of cDNA and 
RNase-free water. Data analysis was performed using Applied Biosystems SDS 2.4 soft-
ware. 
 
Statistical analysis 
Statistical significance was calculated using a paired t-test (SigmaPlot 12.0); all 
experiments were repeated three times. Standard error of mean was measured to all the 
samples. 
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SUMMARY 
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RESULTS 
 
Cytopathic inhibition assay for ACV treated HSV-1 infected L929 cells  
The cytopathic inhibition assay was used to determine which concentration of ACV to 
use for pretreating L929 cells to induce HSV-1 latency after infection with an MOI of 0.1. 
L929 cells treated with 10 µg /ml of ACV were protected from the cytopathic effect of 
HSV-1. No plaques were visible in ACV-treated HSV-1 infected cells in comparison with 
untreated infected control cells (Figure 6). Higher concentrations of ACV (40, 20 µg /ml) 
were protective against the cytopathic effect of HSV-1, but were toxic to L929 cells. 
Eighty percent of the cells treated with 10 µg /ml of ACV survived. However, cells 
treated with 40 µg /ml and 20 µg /ml showed survival levels of 41% and 56%, 
respectively (Figure 7). Cell survival was determined by pixel density measurement using 
the image J program. 
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Figure 6: HSV-1 cytopathic effect at different concentrations of ACV added to L929 
cells before infection. Virus plaques were seen in infected untreated control cells 
(wells 2). There were no plaques in ACV-treated HSV-1 infected cells (wells 8). High 
ACV concentrations were toxic as noticed by the decrease in the cell density (wells 6 
and 7). 
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Figure 7: HSV-1 cytopathic effect at different concentrations of ACV added to L929 
cells before infection. Higher concentrations of ACV have less cell survival after 
HSV-1 infection. Cell survival was determined by measuring % pixel density of 
scanned images. The pixel density was normalized relative to untreated, uninfected 
L929 control cells. ACV (10 µg /ml) treated HSV-1 infected cells have higher 
survival relative to untreated infected control cells; P<0.001 by ANOVA. 
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Comparison of ACV treatment before and after HSV-1 infection 
Treatment of L929 cells with ACV 2 hours after infection resulted in better cell survival 
compared with cells treated with ACV 24 hours before infection (Figure 8). Cell survival 
was 90% using 10 µg /ml of ACV after infection and 80% when using ACV before 
infection. Using a higher concentration of ACV (20 µg /ml) after infection showed better 
survival (82%) compared with same dose before infection (58%), (Figure 9).  The 
explanation for this effect might reflect the time of exposure to ACV, three days in case of 
ACV treatment before infection and only two days in case of ACV treatment after 
infection. Examination of HSV-1 cytopathic effects was carried out at two days post 
infection in both situations. For the subsequent experiments, ACV treatment 24 hours 
before infection was used because ACV treatment after infection inhibited virus 
replication completely. 
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Figure 8: Comparison between HSV-1 cytopathic effects at L929 cells treated with 
ACV before and after infection. Virus plaques were seen in infected untreated 
control cells (wells 2). There were no plaques in ACV treated HSV-1 infected cells 
(wells 5-8). ACV treatment after infection showed better protection from HSV-1 
CPE as noticed by the increase in the cell density (wells 6 and 8). 
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Figure 9: Comparison of HSV-1 cytopathic effects at L929 cells treated with ACV 
before and after infection. ACV treatment after infection has higher cell survival. 
Cell survival was determined by measuring % pixel density of scanned images. The 
pixel density was normalized relative to untreated, uninfected L929 control cells. 
HV-1 infected L929 cells treated with ACV (10 µg /ml) 2 hours after infection 
showed greater survival relative to L929 cells treated with ACV before infection; 
P=0.015 by ANOVA.  A=after infection. B=before infection. 
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HSV-1 latency in L929 cells 
Culture media samples from L929 cells treated 24 hours before HSV-1 infection were 
collected at 48 hours post infection and applied to Vero cell monolayers; no plaques 
formed. This suggested that the virus was silenced in these cells (Figure 10, a). Removal 
of ACV from the culture medium did not cause reactivation of the virus. At 48 hours post 
infection, the culture medium containing ACV was removed and replaced with culture 
medium without ACV, and cells were incubated for an additional 48 hours. At 4 days post 
infection, culture media were collected and applied to Vero cells; there was no plaque 
formation (Figure 11, a), indicating that the virus remained silenced after ACV 
withdrawal. 
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(a)                                                                        (b) 
              
 
                                                                  
                                                             (c) 
 
 
Figure 10: HSV-1 latency in L929 cells and reactivation from lysate. (a) There were 
no plaques in Vero cells overlaid with supernatant from ACV treated HSV-1 infected 
L929 cells. This indicates that the virus is silenced in the L929 cells. (b) There were 
plaques in Vero cells overlaid with lysates from ACV treated HSV-1 infected L929 
cells. This indicates the presence of viable virus in these L929 cells. (c) % Pixel 
density of scanned images was used to measure cell survival. % Pixel density 
normalized against Vero control cells; P= 0.016 by ANOVA. 
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(a)                                                                      (b) 
           
 
 
                                                                            (c) 
 
 
Figure 11: Maintenance HSV-1latency in L929 cells and reactivation by TSA 
treatment. (a) There were no plaques in Vero cells overlaid with supernatant from 
ACV pretreated HSV-1 infected L929 cells after 48 hours of ACV withdrawal. This 
indicates that the virus is still silenced in the L929 cells. (b) There were plaques in 
Vero cells overlaid with supernatants from TSA induced HSV-1 latently infected 
L929 cells. This indicates the presence of reactivated virus in these L929 cells. (c) % 
Pixel density of scanned images was used to measure cell survival. % Pixel density 
normalized against Vero control cells; P=0.003 by ANOVA. 
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N2A cells cytopathic inhibition assay with ACV treatment  
Cytopathic effect assay was conducted to determine the appropriate concentration of 
ACV protecting N2A cells from cytopathic effect of HSV-1. In these experiments N2A 
cells start dying when they reach approximately 80% confluency even without treatment 
and infection. The N2A cells at low confluency about 40-50% were treated with ACV 24 
hours before infection and infected with 0.1 MOI. Using high concentrations of ACV (20, 
10 µg /ml) caused higher cell death (less cell density) than a low concentration of ACV (5 
µg /ml) (Figure 12). The cell survival at low dose of ACV (5 µg /ml) was about 84% 
compared with N2A control cells and at 20 and 10 µg /ml was 44% and 62%, 
respectively (Figure 13). 
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Figure 12: HSV-1 cytopathic effect at different concentrations of ACV treatment of 
N2A cells. Virus plaques were seen in infected untreated control cells (wells 2). There 
were no plaques in infected treated cells (wells 8). High ACV concentrations were 
toxic as noticed by the decrease in the cell density (wells 6 and 7). 
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Figure 13: HSV-1 cytopathic effect at different concentrations of ACV treatment of 
N2A cells. Higher concentrations of ACV lead to lower cell survival after HSV-1 
infection. Cell survival was determined by measuring % pixel density of scanned 
images. The pixel density was normalized relative to untreated, uninfected N2A 
control cells. ACV (5 µg /ml) treated HSV-1 infected cells have higher survival 
relative to untreated infected control cells P=0.003 by ANOVA. 
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HSV-1 latency in N2A cells  
The N2A cells were protected from HSV-1 cytopathic effect by the ACV treatment. The 
latency of the virus in these cells was confirmed by the absence of plaque formation 
when the culture media from ACV-treated HSV-1 infected N2A cells were applied to 
Vero cells (Figure 14, a). Absence of plaques on the Vero cells indicates that the ACV-
treated N2A cells were harboring a quiescent virus. Removal of ACV from the culture 
media did not reactivate the virus. There was no plaque formation on the Vero cells 
overlaid with the culture media from N2A cells after 48 hours of ACV removal (Figure 
15, a). Thus HSV-1latency was maintained in the N2A cells even after ACV withdrawal. 
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(a)                                                                              (b) 
                                                                    
                                                                                
                                                      
                                                                     (c) 
 
 
Figure 14: HSV-1 latency in N2A cells and reactivation from lysate. (a) HSV-1 is 
silenced in the N2A cells. There were no plaques in Vero cells overlaid with 
supernatant from ACV-treated HSV-1 infected N2A cells. (b) ACV-treated HSV-1 
infected N2A cells have viable virus. There were plaques in Vero cells overlaid with 
lysates from ACV-treated HSV-1 infected N2A cells. (c) % Pixel density of scanned 
images was used to measure cell survival. % Pixel density normalized against Vero 
control cells; P=0.009 by ANOVA. 
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(a)                                                                     (b) 
                      
                                                                     
 
                                                                        (c) 
 
 
 
Figure 15: HSV-1 latency in N2A cells and reactivation by TSA treatment. (a) The 
virus is silenced in the N2A cells after ACV withdrawal. There were no plaques in 
Vero cells overlaid with supernatant from ACV pretreated HSV-1 infected N2Acells 
48 hours after ACV withdrawal. (b) There were plaques in Vero cells overlaid with 
supernatants from TSA induced HSV-1 latently infected N2A cells. The plaques 
indicate the presence of reactivated virus in these N2A cells. (c) % Pixel density of 
scanned images was used to measure cell survival. % Pixel density normalized 
against Vero control cells; P< 0.001 by ANOVA. 
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HSV-1 reactivation  
Virus was not reactivated in L929 cells treated with ACV after infection. However, L929 
cells treated with ACV 24 hours before infection showed virus reactivation in cell lysates 
and following TSA treatment. Lysates from ACV treated HSV-1 infected L929 cells were 
titered on Vero cell monolayers. Plaques were seen 2-3 days after lysate application 
(Figure 10, b). The Vero cells survival decreased by about 85% due to presence of the 
reactivated infectious virus in the L929 cells lysate (Figure 10, c). Virus reactivation 
(plaque formation) was observed in 25% of the cultures. L929 cell lysates were prepared 
by two freeze and thaw cycles at -80 °C. In the TSA reactivation, ACV was removed 
from the culture media at 48 hours post infection, and then cells incubated for 48 hours 
without treatment.  At 4 days post infection, culture medium was removed and replaced 
with media containing TSA and cells incubated for an additional 48 hours with TSA in 
the culture media. At 48 hours from TSA treatment, supernatant fluids from the treated 
cultures were applied to Vero cell monolayers and examined daily for plaque formation. 
At the second day post induction, plaques were noticed (Figure 11, b). Vero cells were 
exposed to supernatant fluid from TSA-treated and infected L929 fibroblasts. These 
treated Vero cells showed a 50% survival rate compared to control Vero cells (Figure 11, 
c). The TSA induced HSV-1 reactivation was seen in approximately 31% of the cultures. 
Both cell lysates and TSA treatment of N2A cells induced virus release from latently 
infected N2A cells with subsequent plaque formation on Vero cells (Figure 14, b and 
Figure 15 b). The N2A cells were reactivated in same way as were the L929 cells. In the 
N2A cell lysates, virus reactivation occurred in 15% of the cultures. Virus released from 
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the N2A lysates caused a decrease in the Vero cells survival by about 75% (Figure c). 
Trichostatin A treatment of the N2A cells resulted in virus production from 68% of the 
cultures. Vero cells survival was decreased by about 80% due to presence of the 
reactivated virus in the TSA treated N2A cells supernatant fluids (Figure c).  Virus 
induction with TSA treatment was more powerful than in the cell lysates in both L929 
and N2A cells. 
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Quantitative real-time PCR for HSV-1 transcripts 
Quantitative polymerase chain reactions (qPCR) were conducted at two time periods (16 
hours and 48 hours post infection) in both L929 and N2A cells. In both cell lines, latent 
infection was established by treating the cells with ACV 24 hours before infection.  The 
following day cells were infected with HSV-1 at an MOI of 1. In the ACV-treated, HSV-1 
infected L929 cells at 16 hours post infection, latent infection was confirmed by the 
decrease  in the lytic cycle ICP0 gene transcripts level and increase  in LAT gene 
transcripts level  (around one fold) compared with the untreated HSV-1 infected control 
cells (lytic infection) (Figure  16). At the same time, ICP27 level was elevated in ACV 
treated HSV-1 infected L929 cells about one and half fold compared with HSV-1 infected 
control cells. The cause of this elevation might reflect the presence of some cells being 
lytically infected because latency occurs in only 31% of the cells. At 48 hours post 
infection, there was a decrease in all gene transcripts, however there was a marked 
reduction in ICP27 compared with LAT (P=0.03) (Figure 17). At 48 hours post infection, 
the number of cells was about one fifth of the cells at 16 hours post infection by manual 
cell counting.  In the N2A cells at 16 hours post infection, LAT was observed at low level 
and ICP0 was decreased in ACV-treated HSV-1 infected N2A cells as compared with the 
untreated HSV-1 infected N2A cells. At the same time ICP27 showed approximately one 
fold increase in ACV-treated HSV-1 infected N2A cells as compared with the untreated 
HSV-1 infected N2A cells (Figure 18).  At 48 hours post infection there was a reduction 
in all examined virus genes (Figure 19). The LAT gene was not elevated in the treated 
N2A cells at either time period. The explanation for this observation might be because the 
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viral genes were assessed in the whole cell culture and the latency occurred in 68% of 
cells. Thus, the LAT transcription was masked. Roehm et al., 2011 found that about one 
third only of cells were LAT positive in cultured vestibular ganglion neurons from ACV-
treated HSV-1 infected mice. 
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Figure 16: HSV-1 latency in ACV treated L929 cells and pattern of viral genes 
expression 16 hours post infection. RNA was reverse transcribed and the quantity of 
cDNA synthesized for host and viral transcripts was examined by qPCR. The cDNA 
copies were determined from triplicate reactions. The cDNA copies were normalized 
relative to infected untreated L929 cells (virus control). The virus control was set as 
1 for each transcript. There was one fold increase in the LAT in ACV treated cells 
compared with infected untreated cells. However, this result is statistically 
insignificant; P=0.4 by ANOVA. The increase of ICP27 was not significant 
statistically; P=0.1 by ANOVA. 
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Figure 17: HSV-1 latency in ACV treated L929 cells and pattern of viral gene 
expression 48 hours post infection. RNA was reverse transcribed and the quantity of 
cDNA synthesized for host and viral transcripts was examined by qPCR. The cDNA 
copies were determined from triplicate reactions. The cDNA copies were normalized 
relative to infected untreated L929 cells (virus control). The virus control was set as 
1 for each transcript. There was a decrease in all virus genes in ACV treated HSV-1 
infected cells compared with infected untreated cells. There was a significant 
decrease in ICP27 compared with LAT in ACV-treated HSV-1 infected cells; P=0.03 
by ANOVA. There was a significant decrease in ICP0 in ACV-treated HSV-1 
infected cells compared with infected untreated L929 cells; P<0.001 by ANOVA. 
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Figure 18: HSV-1 latency in N2A cells and pattern of viral gene expression 16 hours 
post infection. RNA was reverse transcribed and the quantity of cDNA synthesized 
for host and viral transcripts was examined by qPCR. The cDNA copies were 
determined from triplicate reactions. The cDNA copies were normalized relative to 
infected untreated N2A cells (virus control). The virus control was set as 1 for each 
transcript. There was an increase in the ICP27 in ACV-treated HSV-1 infected cells 
compared with infected untreated cells. However, this result is statistically 
insignificant; P=0.6 by ANOVA. The decrease in the LAT was not significant 
statistically; P=0.1 by ANOVA. 
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Figure 19: HSV-1 latency in N2A cells and pattern of viral gene expression 48 hours 
post infection. RNA was reverse transcribed and the quantity of cDNA synthesized 
for host and viral transcripts was examined by qPCR. The cDNA copies were 
determined from triplicate reactions. The cDNA copies were normalized relative to 
infected untreated L929 cells (virus control). The virus control was set as 1 for each 
transcript. There was a decrease in all viral genes of ACV treated HSV-1 infected 
N2A cells compared with the control; P<0.001 by ANOVA. 
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Table 1 
 
Quantitative Real-Time PCR primers and probes (Danaher et al., 2005) 
Primer/Probe                      Sequence                                                                 Location
ICP27 F 
  
ICP27 R  
 
ICP27 Probe  
 
CGCCAAGAAAATTTCATCGAG 
 
ACATCTTGCACCACGCCAG 
 
CTGGCCTCCGCCGACGAGAC 
114,766 → 
114,786 
114,811 ← 
114,829 
114,790 → 
114,809 
ICP0 F 
 
 
ICP0 R 
 
 
ICP0 Probe 
CCCTCCAGCCGCATACG 
 
 
CCTCAGAGTCGCTGCTGTCC 
 
 
CAGCGCGAGCCCGCCC 
2,238 → 2,254 
124,117 ← 
124,133 
123,225 → 
123,244 
3,127 ← 3,146 
Probe spans intron 
LAT F 
 
 
LAT R 
 
 
LAT Probe 
CCCACGTACTCCAAGAAGGC 
 
 
AGACCCAAGCATAGAGAGCCAG 
 
 
CCCACCCCGCCTGTGTTTTTGTG 
119,721 → 
119,740 
6,631 ← 6,650 
6,579 → 6,600 
119,771 ← 
119,792 
119,747 → 
119,769 
6,602 ← 6,624 
GAPDHS 
GAPDHA 
GAPDH Probe 
GAACATCATCCCTGCATCCA 
CCAGTGAGCTTCCCGTTCA 
CTTGCCCACAGCCTTGGCAGC 
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DISCUSSION 
 
After primary infection, herpes simplex viruses have the ability to remain latent in 
the neuronal cells with occasional reactivation and shedding during subsequent lytic 
infection. To date, the mechanism for establishment of a quiescent infection and 
reactivation is not well understood. In this study, L929 cells and N2A cells were used as 
models for HSV-1 latency establishment and reactivation in vitro. L929 cells were chosen 
as a model because Scheck et al., 1986 have shown that HSV-1 latency can be established  
in human fetus lung fibroblast (HFL-F) cells by treating them with ACV and interferon-α  
(IFN-α) 24 hours before infection. HSV-1 replication was suppressed in L929 cells 
treated with IFN-γ (Frey et al., 2009). Normal human diploid fibroblasts (NHDFs) 
showed wild type HSV-1 quiescent infection when they were serum starved.  Latency 
was confirmed by accumulation of LATs in these cells (McMahon and Walsh, 2008). 
Neuro-2A cells are mouse neural crest-derived cell lines. N2A cells were chosen because 
they are neuronal phenotype.  
Acyclovir (ACV) has been useful in maintaining HSV-1 latent in many studies in 
vivo and in vitro. Miller et al., 2003 showed that ACV can induce HSV-1 latency in QIF-
PC12 cells and in rabbit eye because ACV does not interfere with viral entry and 
subsequent transmission to the nucleus of PC12 cells. Cytopathic inhibition assays were 
used to determine the appropriate concentration of ACV for suppression of HSV-1 
replication with low cytoxicity to the cell lines. In the L929 cells in this study, high 
concentrations of ACV (40 µg /ml and 20 µg /ml of media) were toxic. However, a low 
concentration of ACV (10 µg /ml of medium) protected L929 cells from the cytopathic 
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effect of HSV-1; no plaques formation resulted, with 80% cell survival in ACV treated 
HSV-1 infected cells compared with HSV-1 infected untreated cells. HSV-1 established 
latency in L929 cells treated with ACV 24 hours before infection. Subsequent virus 
reactivation occurred when ACV-treated, HSV-1 infected L929 cells were treated with 
TSA and cell lysates. On the other hand, treatment of L929 cells with ACV after infection 
was less toxic to the cells than treatment before infection; a suppressed virus replication 
and a quiescent state apparently did not result.  
In N2A cells, low concentration of ACV (5 µg /ml of medium) prevented the 
cytopathic effect of HSV-1 when the cells were treated 24 hours before infection.  This 
concentration was not toxic to the N2A cells with 84% cell survival in comparison with 
higher concentrations of ACV (10 and 20 µg / ml of medium). Establishment of latency 
in both L929 cells and N2A cells was confirmed by absence of virus progeny in the 
culture medium when examined for plaque forming units (PFU). 
HSV-1 latency in L929 cells and N2A cells was maintained even after removal of 
ACV from culture media. Maintenance of latency in ACV treated HSV-1 infected cells 
after ACV withdrawal was confirmed by absence of plaques when the supernatant fluids 
from these cultures were titrated on Vero cells monolayer. This observation is consistent 
with the findings of others (Danaher et al., 2005; Miller et al., 2003; Scheck et al., 1986; 
Danaher et al., 1999a; Danaher et al., 1999b). In contrast, other studies have shown that 
removal of ACV from culture medium of rabbit corneal cells (SIRC) (Rong et al., 1988) 
and cultured vestibular ganglion neurons (VGNs) (Roehm et al., 2011) induced viral 
reactivation from latency. There is no clear explanation for this difference. L929 and N2A 
cell lysates induced decreases in Vero cells survival due to the cytopathic effect of the 
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released HSV-1 virus from ACV-treated latently infected cells. 
Histone acetylation has an impact on HSV-1 reactivation. HSV-1 DNA associated 
with deacetylated histones in human fetal lung fibroblasts (MRC5) quiescently infected 
with replication-defective HSV-1 mutants (Coleman et al., 2008). De-repression of the 
viral genome by HSV-2 superinfection or ICP0 delivery by adenovirus vector revealed 
histone hyperacetylation of HSV-1 genome. The hyperacetylation of histone 3 (H3) 
occurred more at LAT promoter and enhancer than at the other DNA regions following 
genome de-repression (Coleman et al., 2008). Trichostatin A has been used successfully 
to induce HSV-1 reactivation from quiescently infected PC12 cells (Danaher et al., 2005). 
Quantitative real-time polymerase chain reaction revealed that latency- associated 
transcript (LAT) is the only transcript elevated in response to TSA treatment of PC12 
(Danaher et al., 2005). The wild type HSV-1 and LAT mutant HSV-1 were equally 
reactivated in response to TSA treatment. Thus, researchers suggested that LAT does not 
exert a direct role on reactivation from latency. However, Devi-Rao et al., 1994 revealed 
that murine trigeminal and lumbosacral ganglia infected with LAT
- 
mutant showed 
delayed reactivation in comparison with ganglia infected with wild type or LAT
+
 rescuant 
HSV-1. In our study, TSA application to L929 cells and N2A cells for 48 hours caused 
virus release and reactivation from latency. Induction of reactivation from latency was 
observed by plaque formation when supernatant fluid from TSA treated cultures was 
added to Vero cells monolayer.   
As expected, our finding of quantitative real-time PCR (qPCR) revealed an 
increase in LAT expression in ACV treated HSV-1 infected L929 cells 16 hours post 
infection as compared with untreated infected control cells. At same time, ICP0 was 
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decreased, but ICP27 was elevated. A possible explanation for the elevation of lytic gene 
transcript (ICP27) might be that some cells in the culture were undergoing lytic HSV-1 
infection. At 48 hours, all viral genes (LAT, ICP0, and ICP27) were suppressed. The 
decrease of LAT level might because of dying the cells that were latently infected with 
HSV-1. The cells at 48 hours post infection were only one fifth of the cells at 16 hours 
post infection. Previous study in our lab (data not published) showed that only 20-30% of 
FUDR + IFN-γ treated and quiescently HSV-1 infected L929 cells were survive by 
HOECHST staining at 12 hours post infection. In the N2A cells LAT was observed at low 
level and ICP0 was decreased in ACV-treated HSV-1 infected N2A cells as compared 
with the untreated HSV-1 infected N2A cells at 16 hours post infection. At the same time 
ICP27 showed approximately one fold increase in ACV-treated HSV-1 infected N2A cells 
as compared with the untreated HSV-1 infected N2A cells.  At 48 hours post infection, 
LAT, ICP0, and ICP27 were decreased in ACV treated HSV-1 infected cells as compared 
with the control untreated infected cells. The LAT gene was examined in the whole cell 
culture instead of a single cell level. That might mask the LAT gene expression and 
explain why LAT was not high in the ACV-treated HSV-1 infected N2A cells. In vitro, 
about one third only of cells were LAT positive in cultured vestibular ganglion neurons 
after ACV treatment (Roehm et al., 2011). Furthermore, the HSV-1 latency might happen 
in the absence of LAT gene. LAT is not a mandatory for HSV-1 latency establishment 
(Javier et al., 1988; Block et al., 1990). Southern blot analysis of virus gene transcripts 
produced during the establishment and maintenance of latency in quiescently HSV-1 
infected PC12 cells revealed the presence of lytic α gene transcripts. The α gene 
transcripts were maintained as long as 10 days after ACV withdrawal. At the same time, 
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the LAT was consistently expressed (Figure 20) (Danaher et al., 1999a). The qPCR 
results obtained in the present study at 16 hours post-infection are consistent with those 
of Danaher et al., 19991.  While they observed ICP0, ICP4 and ICP27 transcripts along 
with LAT at 5-10 days post infection, LAT transcripts alone was not seen until 20 days 
post infection. 
 
 
 
Figure 20: Southern blot analysis of HSV-1 gene transcripts expressed during 
establishment and maintenance of quiescent infection in PC12 cells (Adapted from 
Dana-her et al., 1999a) 
 
 
In the future, using green fluorescent protein (GFP) to tag HSV-1 DNA would 
provide better visualization of HSV-1 positive cells by microscopic examination.  Roehm 
et al., 2011 used TSA to induce HSV-1 reactivation in cultured vestibular ganglion 
neurons (VGNs) which are HSV-1 GFP positive after ACV removal. After ACV removal, 
the remaining cells were HSV-1 GFP positive. Another advantage for using HSV-1 GFP 
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virus is that HSV-1 can be used at a very low multiplicity of infection (MOI). Kuhn et al., 
2013 infected geniculate ganglion neurons (GGN) with HSV-1 GFP at an MOI of 0.004 
in presence of ACV. In our present study, we noticed elevated LAT only in ACV treated 
HSV-1 infected L929 cells at 16 hours post infection at same time the ICP27 was 
elevated suggesting that either  virus replication had started  and not yet been stopped 
and/or might be because of some of the cells in the cultures did not contain latent virus. 
In our study virus was reactivated from quiescence in 31% of TSA-treated fibroblast 
cultures and in 68% of TSA-treated N2A cultures. If cells containing latent virus can be 
sorted using HSV-1 GFP-tagged DNA and those sorted cells submitted to qPCR analyses 
greater percentages of cultures treated with TSA should yield reactivated HSV-1. 
Previous studies in our lab (data not published) used anti-mitotic agent 5-fluoro 
2’deoxy uridine (FUDR) and IFN- to suppress HSV-1 replication and induce a quiescent 
state in the L929 cells. The virus was silenced in these cells. However, LAT gene was not 
detected in treated HSV-1 infected L929 cells at 16 hours post infection by RT-PCR 
analysis. We can mimic the neurons, which are in post mitotic state by treating the L929 
cells with FUDR and inhibit the HSV-1 replication with ACV treatment to induce HSV-1 
latency in L929 cells in the future studies. 
 Differentiation of N2A cells can be accomplished by serum deprivation or 
treatment with forskolin (cAMP inducer), retinoic acid (RA) (vitamin A derivative), and 2, 
4-dinitrophenol (agent has been known to protect cells from neurotoxicity) (Tremblay et 
al., 2010). Neuronal differentiation methods of N2A cells do not provide information 
about the neuronal types. Differentiation of N2A cells to mimic sympathetic neurons 
might provide better HSV-1 latency. 
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